表紙
市場調查報告書
商品編碼
1052919

全球慢性疼痛治療市場:按產品、適應症、應用、分銷渠道、最終用戶工業收入估計和需求預測(至 2030 年)

Chronic Pain Treatment Market Research Report: By Product, Indication, Application, Distribution Channel, End User - Global Industry Revenue Estimation and Demand Forecast to 2030

出版日期: | 出版商: Prescient & Strategic Intelligence Private Limited | 英文 539 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球慢性疼痛治療市場繼 2020 年達到 807.666 億美元後,2020 年至 2030 年的複合年增長率將達到 7.2%,預計到 2030 年將增長至 1621.752 億美元。

市場的主要驅動力是腰痛、偏頭痛、面部疼痛患者的增加、傾向於坐的生活方式、手術次數的增加以及老年人口的增加。

本報告分析了全球慢性疼痛治療市場,並概述了疾病和流行病學情況、市場基本結構、主要市場促進/抑制因素、實際和預測的市場規模以及產品。我們正在調查詳細趨勢按類型、適應症、用途、分銷渠道、最終用戶、地區、市場競爭狀況、主要公司概況等。

目錄

第 1 章分析背景

第 2 章分析方法

第 3 章執行摘要

第 4 章介紹

  • 細分市場的定義
    • 按產品
      • 製藥
    • 按設備
      • 神經刺激器
      • 止痛藥輸液泵
      • 消融裝置
    • 按指示
      • 神經性疼痛
      • 關節炎疼痛
      • 慢性腰痛
      • 癌痛
      • 偏頭痛
      • 纖維肌痛
      • 其他
    • 按應用
      • 肌肉骨骼
      • 神經紊亂
      • 腫瘤
      • 其他
    • 按分銷渠道
      • 直接
      • 間接
    • 最終用戶
      • 醫院
      • 診所
      • 療養院
      • 研究中心/大學
      • 其他
  • 市場動態
    • 市場趨勢
      • 疼痛管理領域的創新
      • 產品獲批數量增加
    • 促進因素
      • 擴大政府對慢性疼痛管理的支持
      • 老年人口增加
      • 慢性疾病的快速增加
    • 驅動因素對市場預測的影響分析
    • 抑制因素
      • 與疼痛管理藥物和設備相關的副作用
      • 產品召回
      • 用於慢性疼痛治療的百視達專利到期
      • 增加使用阿片類藥物和抗抑鬱藥
    • 抑制因素對市場預測的影響分析
  • 波特五力分析
  • 新型冠狀病毒感染 (COVID-19) 的影響

第 5 章行業考慮

  • 定價和兌換方案
  • 研究經費和政府舉措
  • 慢性疼痛的管道藥物
  • 計劃推出的主要產品
  • 治療

第 6 章流行病學分析

  • 北美:報告的慢性疼痛病例數
  • 歐洲:報告的慢性疼痛病例數
  • 亞太地區:報告的慢性疼痛病例數
  • 拉丁美洲:報告的慢性疼痛病例數
  • 中東/非洲:報告的慢性疼痛病例數

第 7 章全球市場規模與預測

  • 按產品
  • 按指示
  • 按應用
  • 按分銷渠道
  • 最終用戶
  • 按地區

第 8 章北美市場規模及預測

  • 按產品
  • 按指示
  • 按應用
  • 按分銷渠道
  • 最終用戶
  • 按國家/地區
    • 美國
    • 加拿大

第 9 章歐洲市場規模和預測

  • 按產品
  • 按指示
  • 按應用
  • 按分銷渠道
  • 最終用戶
  • 按國家/地區
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 瑞典
    • 瑞士

第 10 章亞太市場規模與預測

  • 按產品
  • 按指示
  • 按應用
  • 按分銷渠道
  • 最終用戶
  • 按國家/地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 韓國

第 11 章拉丁美洲市場規模和預測

  • 按產品
  • 按指示
  • 按應用
  • 按分銷渠道
  • 最終用戶
  • 按國家/地區
    • 巴西
    • 墨西哥

第 12 章中東/非洲市場規模和預測

  • 按產品
  • 按指示
  • 按應用
  • 按分銷渠道
  • 最終用戶
  • 按國家/地區
    • 沙特阿拉伯
    • 南非

第 13 章競爭態勢

  • 各大公司的產品標桿
  • 各大公司戰略發展現狀
    • 夥伴關係、合作、合同
    • 併購(併購)
    • 產品發佈和批准

第 14 章公司簡介

  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Medtronic plc
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Novartis AG
  • Johnson & Johnson
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Becton, Dickinson and Company
  • Sanofi S.A.

第 15 章附錄

目錄
Product Code: LS10758

The global chronic pain treatment market valued $80,766.6 million in 2020, from where it is set to reach $162,175.2 million by 2030, at a 7.2% CAGR between 2020 and 2030. This will be majorly because of the geriatric population, which, as per the United Nations (UN), will increase from 727 million in 2020 to 1.5 billion by 2050. With age, people become prone to several health issues, including chronic pain because of arthritis, muscle strain, posture issues, and other reasons.

Most patients purchase drugs and devices for the treatment of chronic pain associated with musculoskeletal conditions, such as osteoarthritis, rheumatoid arthritis, and fibromyalgia. For instance, in 2017, 8.7 million osteoarthritis patients in the age group of 45 and above were treated in the U.K., says Arthritis Research U.K. Hence, on account of the rising prevalence of bone and muscle diseases, the demand for chronic pain treatment products is surging.

Key Findings of Chronic Pain Treatment Market Report:

  • Drugs witness the higher sales due to the surging number of people with lower back pain, migraine pain or severe headache, and facial pain. This is itself a result of the sedentary lifestyle, increasing surgery volume, and booming geriatric population.
  • In the coming years, drugs and devices will be procured in the highest volumes to treat chronic cancer pain, due to the rising incidence of this disease. As tumors tear through tissues, muscles, bones, skin, and blood vessels, they cause extreme pain.
  • Revenue generation for chronic pain treatment market players through direct distribution channels is set to rise faster in the coming years. This way, at-home patients participating in clinical trials get faster access to treatments.
  • The COVID-19 pandemic has boosted the demand for chronic pain treatment drugs and devices by creating stress among people with pre-existing health issues, which ended up causing them long-term pain.
  • North America witnesses the highest sale of these products because of the high health awareness, developed medical infrastructure, and increasing cases of chronic diseases, such as cancer and heart diseases.
  • Seeing the rising number of people with chronic pain, healthcare companies are bringing about innovations in wearable medical devices and non-opioid pain medication.
  • The fastest chronic pain treatment market growth is expected to be witnessed in Asia-Pacific (APAC), which, being the most-populated region, is home to a huge patient pool. Thus, the growing geriatric population and number of people with chronic diseases, combined with the increasing awareness on chronic pain, offer lucrative opportunities to market players.
  • Key companies in the chronic pain treatment market include: Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Novartis AG, AstraZeneca plc, Johnson & Johnson, Bristol-Myers Squibb Company, Sanofi S.A., and Becton, Dickinson and Company. To gain the upper hand, they are engaging in partnerships, product launches, and partnerships.

Table of Contents

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Market Definition
  • 1.3 Research Scope
    • 1.3.1 Market Segmentation by Product
    • 1.3.2 Market Segmentation by Indication
    • 1.3.3 Market Segmentation by Application
    • 1.3.4 Market Segmentation by Distribution Channel
    • 1.3.5 Market Segmentation by End User
    • 1.3.6 Market Segmentation by Region
    • 1.3.7 Analysis Period
    • 1.3.8 Market Data Reporting Unit
      • 1.3.8.1 Value
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 Breakdown of Primary Research Respondents
      • 2.2.1.1 By region
      • 2.2.1.2 By industry participant
      • 2.2.1.3 By company type
  • 2.3 Market Size Estimation
  • 2.4 Data Triangulation
  • 2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

  • 4.1 Definition of Market Segments
    • 4.1.1 By Product
      • 4.1.1.1 Drugs
        • 4.1.1.1.1 Opioids
        • 4.1.1.1.2 NSAIDs
        • 4.1.1.1.3 Anticonvulsants
        • 4.1.1.1.4 Antidepressants
        • 4.1.1.1.5 Others
    • 4.1.2 By Devices
      • 4.1.2.1 Neurostimulation devices
        • 4.1.2.1.1 SCS
        • 4.1.2.1.2 TENS
        • 4.1.2.1.3 Others
      • 4.1.2.2 Analgesic infusion pumps
      • 4.1.2.3 Ablation devices
        • 4.1.2.3.1 Radiofrequency ablation devices
        • 4.1.2.3.2 Cryoablation devices
    • 4.1.3 By Indication
      • 4.1.3.1 Neuropathic pain
      • 4.1.3.2 Arthritis pain
      • 4.1.3.3 Chronic back pain
      • 4.1.3.4 Cancer pain
      • 4.1.3.5 Migraine
      • 4.1.3.6 Fibromyalgia
      • 4.1.3.7 Others
    • 4.1.4 By Application
      • 4.1.4.1 Musculoskeletal
      • 4.1.4.2 Neuropathy
      • 4.1.4.3 Oncology
      • 4.1.4.4 Others
    • 4.1.5 By Distribution channel
      • 4.1.5.1 Direct
      • 4.1.5.2 Indirect
    • 4.1.6 By End User
      • 4.1.6.1 Hospitals
      • 4.1.6.2 Clinics
      • 4.1.6.3 Nursing homes
      • 4.1.6.4 Research centers & universities
      • 4.1.6.5 Others
  • 4.2 Market Dynamics
    • 4.2.1 Trends
      • 4.2.1.1 Innovations in the field of pain management
      • 4.2.1.2 Increasing number of product approvals
    • 4.2.2 Drivers
      • 4.2.2.1 Increasing government support for chronic pain management
      • 4.2.2.2 Growing geriatric population
      • 4.2.2.3 Surging prevalence of chronic health conditions
    • 4.2.3 Impact Analysis of Drivers on Market Forecast
    • 4.2.4 Restraints
      • 4.2.4.1 Side effects associated with pain management drugs and devices
      • 4.2.4.2 Product recalls
      • 4.2.4.3 Patent expiry of blockbuster chronic pain treatment drugs
      • 4.2.4.4 Increasing usage of opioids and antidepressants
    • 4.2.5 Impact Analysis of Restraints on Market Forecast
  • 4.3 Porter's Five Forces Analysis
  • 4.4 Impact of COVID-19

Chapter 5. Industry Insights

  • 5.1 Pricing and Reimbursement Scenario
    • 5.1.1 Pricing
    • 5.1.2 Reimbursement Scenario
      • 5.1.2.1 U.S.
      • 5.1.2.2 Canada
      • 5.1.2.3 Europe
        • 5.1.2.3.1 Italy
        • 5.1.2.3.2 Germany
        • 5.1.2.3.3 U.K.
      • 5.1.2.4 Japan
      • 5.1.2.5 Australia
  • 5.2 Research Funding and Government Initiatives
  • 5.3 Pipeline Drugs for Chronic Pain
  • 5.4 Key Products Expected to be Launched
  • 5.5 Treatment

Chapter 6. Epidemiology Analysis

  • 6.1 Number of People Reported with Chronic Pain in North America
    • 6.1.1 U.S.
      • 6.1.1.1 Patients visited healthcare facilities for the management of chronic pain in U.S.
        • 6.1.1.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in U.S.
    • 6.1.2 Canada
      • 6.1.2.1 Patients visited healthcare facilities for the management of chronic pain in Canada
        • 6.1.2.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Canada
  • 6.2 Number of People Reported with Chronic Pain in Europe
    • 6.2.1 Germany
      • 6.2.1.1 Patients visited healthcare facilities for the management of chronic pain in Germany
        • 6.2.1.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Germany
    • 6.2.2 France
      • 6.2.2.1 Patients visited healthcare facilities for the management of chronic pain in France
        • 6.2.2.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in France
    • 6.2.3 U.K.
      • 6.2.3.1 Patients visited healthcare facilities for the management of chronic pain in U.K.
        • 6.2.3.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in U.K.
    • 6.2.4 Italy
      • 6.2.4.1 Patients visited healthcare facilities for the management of chronic pain in Italy
        • 6.2.4.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Italy
    • 6.2.5 Spain
      • 6.2.5.1 Patients visited healthcare facilities for the management of chronic pain in Spain
        • 6.2.5.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Spain
    • 6.2.6 Netherlands
      • 6.2.6.1 Patients visited healthcare facilities for the management of chronic pain in Netherlands
        • 6.2.6.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Netherlands
    • 6.2.7 Russia
      • 6.2.7.1 Patients visited healthcare facilities for the management of chronic pain in Russia
        • 6.2.7.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Russia
    • 6.2.8 Sweden
      • 6.2.8.1 Patients visited healthcare facilities for the management of chronic pain in Sweden
        • 6.2.8.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Sweden
    • 6.2.9 Switzerland
      • 6.2.9.1 Patients visited healthcare facilities for the management of chronic pain in Switzerland
        • 6.2.9.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Switzerland
  • 6.3 Number of People Reported with Chronic Pain in APAC
    • 6.3.1 Japan
      • 6.3.1.1 Patients visited healthcare facilities for the management of chronic pain in Japan
        • 6.3.1.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Japan
    • 6.3.2 China
      • 6.3.2.1 Patients visited healthcare facilities for the management of chronic pain in China
        • 6.3.2.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in China
    • 6.3.3 India
      • 6.3.3.1 Patients visited healthcare facilities for the management of chronic pain in India
        • 6.3.3.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in India
    • 6.3.4 Australia
      • 6.3.4.1 Patients visited healthcare facilities for the management of chronic pain in Australia
        • 6.3.4.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Australia
    • 6.3.5 South Korea
      • 6.3.5.1 Patients visited healthcare facilities for the management of chronic pain in South Korea
        • 6.3.5.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in South Korea
  • 6.4 Number of People Reported with Chronic Pain in LATAM
    • 6.4.1 Brazil
      • 6.4.1.1 Patients visited healthcare facilities for the management of chronic pain in Brazil
        • 6.4.1.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Brazil
    • 6.4.2 Mexico
      • 6.4.2.1 Patients visited healthcare facilities for the management of chronic pain in Mexico
        • 6.4.2.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Mexico
  • 6.5 Number of People Reported with Chronic Pain in MEA
    • 6.5.1 Saudi Arabia
      • 6.5.1.1 Patients visited healthcare facilities for the management of chronic pain in Saudi Arabia
        • 6.5.1.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in Saudi Arabia
    • 6.5.2 South Africa
      • 6.5.2.1 Patients visited healthcare facilities for the management of chronic pain in South Africa
        • 6.5.2.1.1 Percentage of patients visited different healthcare settings for management of chronic pain in South Africa

Chapter 7. Global Market Size and Forecast

  • 7.1 By Product
    • 7.1.1 Chronic Pain Drugs Market, by Type
    • 7.1.2 Chronic Pain Devices Market, by Type
      • 7.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
      • 7.1.2.2 Ablation devices market for chronic pain treatment, by type
  • 7.2 By Indication
  • 7.3 By Application
  • 7.4 By Distribution Channel
  • 7.5 By End User
  • 7.6 By Region

Chapter 8. North America Market Size and Forecast

  • 8.1 By Product
    • 8.1.1 Chronic Pain Drugs Market, by Type
    • 8.1.2 Chronic Pain Devices Market, by Type
      • 8.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
      • 8.1.2.2 Ablation devices market for chronic pain treatment, by type
  • 8.2 By Indication
  • 8.3 By Application
  • 8.4 By Distribution Channel
  • 8.5 By End User
  • 8.6 By Country
    • 8.6.1 U.S. Market Size and Forecast
      • 8.6.1.1 By product
        • 8.6.1.1.1 Chronic pain drugs market, by type
        • 8.6.1.1.2 Chronic pain devices market, by type
        • 8.6.1.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 8.6.1.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 8.6.1.2 By indication
      • 8.6.1.3 By application
      • 8.6.1.4 By distribution channel
      • 8.6.1.5 By end user
    • 8.6.2 Canada Market Size and Forecast
      • 8.6.2.1 By product
        • 8.6.2.1.1 Chronic pain drugs market, by type
        • 8.6.2.1.2 Chronic pain devices market, by type
        • 8.6.2.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 8.6.2.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 8.6.2.2 By indication
      • 8.6.2.3 By application
      • 8.6.2.4 By distribution channel
      • 8.6.2.5 By end user

Chapter 9. Europe Market Size and Forecast

  • 9.1 By Product
    • 9.1.1 Chronic Pain Drugs Market, by Type
    • 9.1.2 Chronic Pain Devices Market, by Type
      • 9.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
      • 9.1.2.2 Ablation devices market for chronic pain treatment, by type
  • 9.2 By Indication
  • 9.3 By Application
  • 9.4 By Distribution Channel
  • 9.5 By End User
  • 9.6 By Country
    • 9.6.1 Germany Market Size and Forecast
      • 9.6.1.1 By product
        • 9.6.1.1.1 Chronic pain drugs market, by type
        • 9.6.1.1.2 Chronic pain devices market, by type
        • 9.6.1.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 9.6.1.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 9.6.1.2 By indication
      • 9.6.1.3 By application
      • 9.6.1.4 By distribution channel
      • 9.6.1.5 By end user
    • 9.6.2 France Market Size and Forecast
      • 9.6.2.1 By product
        • 9.6.2.1.1 Chronic pain drugs market, by type
        • 9.6.2.1.2 Chronic pain devices market, by type
        • 9.6.2.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 9.6.2.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 9.6.2.2 By indication
      • 9.6.2.3 By application
      • 9.6.2.4 By distribution channel
      • 9.6.2.5 By end user
    • 9.6.3 U.K. Market Size and Forecast
      • 9.6.3.1 By product
        • 9.6.3.1.1 Chronic pain drugs market, by type
        • 9.6.3.1.2 Chronic pain devices market, by type
        • 9.6.3.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 9.6.3.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 9.6.3.2 By indication
      • 9.6.3.3 By application
      • 9.6.3.4 By distribution channel
      • 9.6.3.5 By end user
    • 9.6.4 Italy Market Size and Forecast
      • 9.6.4.1 By product
        • 9.6.4.1.1 Chronic pain drugs market, by type
        • 9.6.4.1.2 Chronic pain devices market, by type
        • 9.6.4.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 9.6.4.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 9.6.4.2 By indication
      • 9.6.4.3 By application
      • 9.6.4.4 By distribution channel
      • 9.6.4.5 By end user
    • 9.6.5 Spain Market Size and Forecast
      • 9.6.5.1 By product
        • 9.6.5.1.1 Chronic pain drugs market, by type
        • 9.6.5.1.2 Chronic pain devices market, by type
        • 9.6.5.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 9.6.5.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 9.6.5.2 By indication
      • 9.6.5.3 By application
      • 9.6.5.4 By distribution channel
      • 9.6.5.5 By end user
    • 9.6.6 Netherlands Market Size and Forecast
      • 9.6.6.1 By product
        • 9.6.6.1.1 Chronic pain drugs market, by type
        • 9.6.6.1.2 Chronic pain devices market, by type
        • 9.6.6.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 9.6.6.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 9.6.6.2 By indication
      • 9.6.6.3 By application
      • 9.6.6.4 By distribution channel
      • 9.6.6.5 By end user
    • 9.6.7 Russia Market Size and Forecast
      • 9.6.7.1 By product
        • 9.6.7.1.1 Chronic pain drugs market, by type
        • 9.6.7.1.2 Chronic pain devices market, by type
        • 9.6.7.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 9.6.7.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 9.6.7.2 By indication
      • 9.6.7.3 By application
      • 9.6.7.4 By distribution channel
      • 9.6.7.5 By end user
    • 9.6.8 Sweden Market Size and Forecast
      • 9.6.8.1 By product
        • 9.6.8.1.1 Chronic pain drugs market, by type
        • 9.6.8.1.2 Chronic pain devices market, by type
        • 9.6.8.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 9.6.8.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 9.6.8.2 By indication
      • 9.6.8.3 By application
      • 9.6.8.4 By distribution channel
      • 9.6.8.5 By end user
    • 9.6.9 Switzerland Market Size and Forecast
      • 9.6.9.1 By product
        • 9.6.9.1.1 Chronic pain drugs market, by type
        • 9.6.9.1.2 Chronic pain devices market, by type
        • 9.6.9.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 9.6.9.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 9.6.9.2 By indication
      • 9.6.9.3 By application
      • 9.6.9.4 By distribution channel
      • 9.6.9.5 By end user

Chapter 10. APAC Market Size and Forecast

  • 10.1 By Product
    • 10.1.1 Chronic Pain Drugs Market, by Type
    • 10.1.2 Chronic Pain Devices Market, by Type
      • 10.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
      • 10.1.2.2 Ablation devices market for chronic pain treatment, by type
  • 10.2 By Indication
  • 10.3 By Application
  • 10.4 By Distribution Channel
  • 10.5 By End User
  • 10.6 By Country
    • 10.6.1 Japan Market Size and Forecast
      • 10.6.1.1 By product
        • 10.6.1.1.1 Chronic pain drugs market, by type
        • 10.6.1.1.2 Chronic pain devices market, by type
        • 10.6.1.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 10.6.1.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 10.6.1.2 By indication
      • 10.6.1.3 By application
      • 10.6.1.4 By distribution channel
      • 10.6.1.5 By end user
    • 10.6.2 China Market Size and Forecast
      • 10.6.2.1 By product
        • 10.6.2.1.1 Chronic pain drugs market, by type
        • 10.6.2.1.2 Chronic pain devices market, by type
        • 10.6.2.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 10.6.2.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 10.6.2.2 By indication
      • 10.6.2.3 By application
      • 10.6.2.4 By distribution channel
      • 10.6.2.5 By end user
    • 10.6.3 India Market Size and Forecast
      • 10.6.3.1 By product
        • 10.6.3.1.1 Chronic pain drugs market, by type
        • 10.6.3.1.2 Chronic pain devices market, by type
        • 10.6.3.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 10.6.3.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 10.6.3.2 By indication
      • 10.6.3.3 By application
      • 10.6.3.4 By distribution channel
      • 10.6.3.5 By end user
    • 10.6.4 Australia Market Size and Forecast
      • 10.6.4.1 By product
        • 10.6.4.1.1 Chronic pain drugs market, by type
        • 10.6.4.1.2 Chronic pain devices market, by type
        • 10.6.4.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 10.6.4.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 10.6.4.2 By indication
      • 10.6.4.3 By application
      • 10.6.4.4 By distribution channel
      • 10.6.4.5 By end user
    • 10.6.5 South Korea Market Size and Forecast
      • 10.6.5.1 By product
        • 10.6.5.1.1 Chronic pain drugs market, by type
        • 10.6.5.1.2 Chronic pain devices market, by type
        • 10.6.5.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 10.6.5.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 10.6.5.2 By indication
      • 10.6.5.3 By application
      • 10.6.5.4 By distribution channel
      • 10.6.5.5 By end user

Chapter 11. LATAM Market Size and Forecast

  • 11.1 By Product
    • 11.1.1 Chronic Pain Drugs Market, by Type
    • 11.1.2 Chronic Pain Devices Market, by Type
      • 11.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
      • 11.1.2.2 Ablation devices market for chronic pain treatment, by type
  • 11.2 By Indication
  • 11.3 By Application
  • 11.4 By Distribution Channel
  • 11.5 By End User
  • 11.6 By Country
    • 11.6.1 Brazil Market Size and Forecast
      • 11.6.1.1 By product
        • 11.6.1.1.1 Chronic pain drugs market, by type
        • 11.6.1.1.2 Chronic pain devices market, by type
        • 11.6.1.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 11.6.1.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 11.6.1.2 By indication
      • 11.6.1.3 By application
      • 11.6.1.4 By distribution channel
      • 11.6.1.5 By end user
    • 11.6.2 Mexico Market Size and Forecast
      • 11.6.2.1 By product
        • 11.6.2.1.1 Chronic pain drugs market, by type
        • 11.6.2.1.2 Chronic pain devices market, by type
        • 11.6.2.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 11.6.2.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 11.6.2.2 By indication
      • 11.6.2.3 By application
      • 11.6.2.4 By distribution channel
      • 11.6.2.5 By end user

Chapter 12. MEA Market Size and Forecast

  • 12.1 By Product
    • 12.1.1 Chronic Pain Drugs Market, by Type
    • 12.1.2 Chronic Pain Devices Market, by Type
      • 12.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
      • 12.1.2.2 Ablation devices market for chronic pain treatment, by type
  • 12.2 By Indication
  • 12.3 By Application
  • 12.4 By Distribution Channel
  • 12.5 By End User
  • 12.6 By Country
    • 12.6.1 Saudi Arabia Market Size and Forecast
      • 12.6.1.1 By product
        • 12.6.1.1.1 Chronic pain drugs market, by type
        • 12.6.1.1.2 Chronic pain devices market, by type
        • 12.6.1.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 12.6.1.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 12.6.1.2 By indication
      • 12.6.1.3 By application
      • 12.6.1.4 By distribution channel
      • 12.6.1.5 By end user
    • 12.6.2 South Africa Market Size and Forecast
      • 12.6.2.1 By product
        • 12.6.2.1.1 Chronic pain drugs market, by type
        • 12.6.2.1.2 Chronic pain devices market, by type
        • 12.6.2.1.2.1 Neurostimulation devices market for chronic pain treatment, by type
        • 12.6.2.1.2.2 Ablation devices market for chronic pain treatment, by type
      • 12.6.2.2 By indication
      • 12.6.2.3 By application
      • 12.6.2.4 By distribution channel
      • 12.6.2.5 By end user

Chapter 13. Competitive Landscape

  • 13.1 Product Benchmarking of Key Players
  • 13.2 Strategic Developments of Key Players
    • 13.2.1 Partnerships, Collaborations, and Agreements
    • 13.2.2 Mergers and Acquisitions
    • 13.2.3 Product Launches and Approvals

Chapter 14. Company Profiles

  • 14.1 Eli Lilly and Company
    • 14.1.1 Business Overview
    • 14.1.2 Product and Service Offerings
      • 14.1.2.1 Marketed products
      • 14.1.2.2 Pipeline products
    • 14.1.3 Key Financial Summary
  • 14.2 GlaxoSmithKline plc
    • 14.2.1 Business Overview
    • 14.2.2 Product and Service Offerings
      • 14.2.2.1 Marketed products
      • 14.2.2.2 Pipeline products
    • 14.2.3 Key Financial Summary
  • 14.3 Pfizer Inc.
    • 14.3.1 Business Overview
    • 14.3.2 Product and Service Offerings
      • 14.3.2.1 Marketed products
      • 14.3.2.2 Pipeline products
    • 14.3.3 Key Financial Summary
  • 14.4 Medtronic plc
    • 14.4.1 Business Overview
    • 14.4.2 Product and Service Offerings
    • 14.4.3 Key Financial Summary
  • 14.5 Abbott Laboratories
    • 14.5.1 Business Overview
    • 14.5.2 Product and Service Offerings
    • 14.5.3 Key Financial Summary
  • 14.6 Boston Scientific Corporation
    • 14.6.1 Business Overview
    • 14.6.2 Product and Service Offerings
    • 14.6.3 Key Financial Summary
  • 14.7 Novartis AG
    • 14.7.1 Business Overview
    • 14.7.2 Product and Service Offerings
      • 14.7.2.1 Marketed products
      • 14.7.2.2 Pipeline products
    • 14.7.3 Key Financial Summary
  • 14.8 Johnson & Johnson
    • 14.8.1 Business Overview
    • 14.8.2 Product and Service Offerings
      • 14.8.2.1 Marketed products
      • 14.8.2.2 Pipeline products
    • 14.8.3 Key Financial Summary
  • 14.9 AstraZeneca plc
    • 14.9.1 Business Overview
    • 14.9.2 Product and Service Offerings
      • 14.9.2.1 Marketed products
      • 14.9.2.2 Pipeline products
    • 14.9.3 Key Financial Summary
  • 14.10 Bristol-Myers Squibb Company
    • 14.10.1 Business Overview
    • 14.10.2 Product and Service Offerings
      • 14.10.2.1 Marketed products
      • 14.10.2.2 Pipeline products
    • 14.10.3 Key Financial Summary
  • 14.11 Becton, Dickinson and Company
    • 14.11.1 Business Overview
    • 14.11.2 Product and Service Offerings
    • 14.11.3 Key Financial Summary
  • 14.12 Sanofi S.A.
    • 14.12.1 Business Overview
    • 14.12.2 Product and Service Offerings
      • 14.12.2.1 Marketed products
      • 14.12.2.2 Pipeline products
    • 14.12.3 Key Financial Summary

Chapter 15. Appendix

  • 15.1 Abbreviations
  • 15.2 Sources and References
  • 15.3 Related Reports

LIST OF FIGURES

  • FIG 1 RESEARCH SCOPE
  • FIG 2 RESEARCH METHODOLOGY
  • FIG 3 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY REGION
  • FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
  • FIG 6 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
  • FIG 7 DATA TRIANGULATION APPROACH
  • FIG 8 GLOBAL CHRONIC PAIN TREATMENT MARKET SUMMARY
  • FIG 9 BARGAINING POWER OF BUYERS
  • FIG 10 BARGAINING POWER OF SUPPLIERS
  • FIG 11 INTENSITY OF RIVALRY
  • FIG 12 THREAT OF NEW ENTRANTS
  • FIG 13 THREAT OF SUBSTITUTES
  • FIG 14 TREATMENT PROCEDURES FOR CHRONIC PAIN
  • FIG 15 SNAPSHOT OF GLOBAL CHRONIC PAIN TREATMENT MARKET, BY PRODUCT, 2020
  • FIG 16 GLOBAL CHRONIC PAIN TREATMENT MARKET, BY PRODUCT, $M (2015-2030)
  • FIG 17 GLOBAL CHRONIC PAIN TREATMENT MARKET, BY INDICATION, $M (2015-2030)
  • FIG 18 GLOBAL CHRONIC PAIN TREATMENT MARKET, BY APPLICATION, $M (2015-2030)
  • FIG 19 GLOBAL CHRONIC PAIN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, $M (2015-2030)
  • FIG 20 GLOBAL CHRONIC PAIN TREATMENT MARKET, BY END USER, $M (2015-2030)
  • FIG 21 NORTH AMERICA CHRONIC PAIN TREATMENT MARKET SNAPSHOT
  • FIG 22 NORTH AMERICA CHRONIC PAIN TREATMENT MARKET, BY PRODUCT, $M (2015-2030)
  • FIG 23 NORTH AMERICA CHRONIC PAIN TREATMENT MARKET, BY INDICATION, $M (2015-2030)
  • FIG 24 NORTH AMERICA CHRONIC PAIN TREATMENT MARKET, BY APPLICATION, $M (2015-2030)
  • FIG 25 NORTH AMERICA CHRONIC PAIN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, $M (2015-2030)
  • FIG 26 NORTH AMERICA CHRONIC PAIN TREATMENT MARKET, BY END USER, $M (2015-2030)
  • FIG 27 NORTH AMERICA CHRONIC PAIN TREATMENT MARKET, BY COUNTRY, $M (2015-2030)
  • FIG 28 EUROPE CHRONIC PAIN TREATMENT MARKET SNAPSHOT
  • FIG 29 EUROPE CHRONIC PAIN TREATMENT MARKET, BY PRODUCT, $M (2015-2030)
  • FIG 30 EUROPE CHRONIC PAIN TREATMENT MARKET, BY INDICATION, $M (2015-2030)
  • FIG 31 EUROPE CHRONIC PAIN TREATMENT MARKET, BY APPLICATION, $M (2015-2030)
  • FIG 32 EUROPE CHRONIC PAIN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, $M (2015-2030)
  • FIG 33 EUROPE CHRONIC PAIN TREATMENT MARKET, BY END USER, $M (2015-2030)
  • FIG 34 EUROPE CHRONIC PAIN TREATMENT MARKET, BY COUNTRY, $M (2015-2030)
  • FIG 35 APAC CHRONIC PAIN TREATMENT MARKET SNAPSHOT
  • FIG 36 APAC CHRONIC PAIN TREATMENT MARKET, BY PRODUCT, $M (2015-2030)
  • FIG 37 APAC CHRONIC PAIN TREATMENT MARKET, BY INDICATION, $M (2015-2030)
  • FIG 38 APAC CHRONIC PAIN TREATMENT MARKET, BY APPLICATION, $M (2015-2030)
  • FIG 39 APAC CHRONIC PAIN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, $M (2015-2030)
  • FIG 40 APAC CHRONIC PAIN TREATMENT MARKET, BY END USER, $M (2015-2030)
  • FIG 41 APAC CHRONIC PAIN TREATMENT MARKET, BY COUNTRY, $M (2015-2030)
  • FIG 42 LATAM CHRONIC PAIN TREATMENT MARKET SNAPSHOT
  • FIG 43 LATAM CHRONIC PAIN TREATMENT MARKET, BY PRODUCT, $M (2015-2030)
  • FIG 44 LATAM CHRONIC PAIN TREATMENT MARKET, BY INDICATION, $M (2015-2030)
  • FIG 45 LATAM CHRONIC PAIN TREATMENT MARKET, BY APPLICATION, $M (2015-2030)
  • FIG 46 LATAM CHRONIC PAIN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, $M (2015-2030)
  • FIG 47 LATAM CHRONIC PAIN TREATMENT MARKET, BY END USER, $M (2015-2030)
  • FIG 48 LATAM CHRONIC PAIN TREATMENT MARKET, BY COUNTRY, $M (2015-2030)
  • FIG 49 MEA CHRONIC PAIN TREATMENT MARKET SNAPSHOT
  • FIG 50 MEA CHRONIC PAIN TREATMENT MARKET, BY PRODUCT, $M (2015-2030)
  • FIG 51 MEA CHRONIC PAIN TREATMENT MARKET, BY INDICATION, $M (2015-2030)
  • FIG 52 MEA CHRONIC PAIN TREATMENT MARKET, BY APPLICATION, $M (2015-2030)
  • FIG 53 MEA CHRONIC PAIN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, $M (2015-2030)
  • FIG 54 MEA CHRONIC PAIN TREATMENT MARKET, BY END USER, $M (2015-2030)
  • FIG 55 MEA CHRONIC PAIN TREATMENT MARKET, BY COUNTRY, $M (2015-2030)
  • FIG 56 PRODUCT BENCHMARKING OF KEY PLAYERS IN CHRONIC PAIN TREATMENT DRUGS MARKET
  • FIG 57 PRODUCT BENCHMARKING OF KEY PLAYERS IN CHRONIC PAIN TREATMENT DEVICES MARKET
  • FIG 58 ELI LILLY AND COMPANY - REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2020)
  • FIG 59 GLAXOSMITHKLINE PLC - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
  • FIG 60 PFIZER INC. - REVENUE SPLIT BY PRODUCT AND GEOGRAPHY (2020)
  • FIG 61 MEDTRONIC PLC - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2021)
  • FIG 62 ABBOTT LABORATORIES - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
  • FIG 63 BOSTON SCIENTIFIC CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
  • FIG 64 NOVARTIS AG - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
  • FIG 65 JOHNSON & JOHNSON - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
  • FIG 66 ASTRAZENECA PLC - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
  • FIG 67 BRISTOL-MYERS SQUIBB COMPANY - REVENUE SPLIT BY BRAND AND GEOGRAPHY (2020)
  • FIG 68 BECTON, DICKINSON AND COMPANY - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
  • FIG 69 SANOFI S.A. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)